Safety and Pharmacokinetics of a Single ZMappTM Administration in Healthy Adult Volunteers

Ebola virus (EBOV) is associated with high morbidity and mortality rates in patients
presenting clinical illness. Currently, no agent is approved in the U.S. or elsewhere for the
therapeutic treatment of EBOV. The current standard of care for EBOV infection is limited to
supportive treatment.

ZMapp TM, a combination of three chimeric human/murine monoclonal antibodies against the EBOV
surface glycoprotein found on virions and infected cells, is being developed as a treatment
for Ebola virus disease. This is a Phase 1a, open-label study to assess the safety and
pharmacokinetics of a single intravenous administration of ZMapp tm in healthy adult
volunteers. Three subjects will receive a single intravenous dose of 50mg/kg infusion and be
evaluated on study Days 0, 1, 2, 7, 14, 21, 28, 60, and 90. Samples will be collected for
pharmacokinetic and immunogenicity assessments at baseline, during, and following infusion.
Subjects will be monitored and assessed for safety and the incidence of adverse events over
the course of the study.

- INCLUSION CRITERIA:

1. Adult healthy volunteers 18 to 50 years of age, inclusive.

2. Able to understand and provide written informed consent.

3. Body mass index 18 kg/m2 to 29 kg/m2, inclusive, at time of screening.

4. Female subjects must be of non-childbearing potential (e.g., be confirmed
postmenopausal or have undergone surgical sterilization) or must, in conjunction
with their sexual partner(s), use a highly effective contraceptive (namely, a
long-acting reversible method (IUD, injectable, or implant), or a combination of
oral contraception in conjunction with a male condom) during the screening period
and for at least 30 days after the infusion of study medication.

5. Male subjects must either be sterile or agree to use, for the entire duration of
the study, a male condom; the female sexual partner must also use a medically
acceptable form of birth control (e.g., oral contraceptives), or a highly
effective contraceptive (as described in #4 above).

6. Male subjects must agree to not donate sperm for at least 30 days after the
infusion of study medication.

EXCLUSION CRITERIA:

1. Pregnancy or breastfeeding.

2. A positive urine or blood screen for drugs of abuse at time of screening.

3. Prior use of any medical intervention involving antibody products.

4. Active substance abuse or any medical or psychiatric condition that, in the opinion of
the principal investigator, could jeopardize the subject's safety or the subject's
ability to comply with the protocol requirements.

5. Any chronic medical problem that requires daily medications (except Tylenol, oral
contraceptives, vitamins, eye drops, and seasonal allergy medications), or other
medical history that in the opinion of the investigator significantly increases the
risk associated with a Phase 1 drug.

6. Allergy or intolerance of antihistamines, acetominophen, or catabolic steroids.

7. Active participation in any interventional clinical trial within 6 months prior to the
dosing on Day 0 (i.e., received any other investigational drug).

8. Prolonged QTcF interval > 440 ms for males or > 460 ms for females.

9. Other clinically significant ECG abnormality, as determined by the principal
investigator.

10. Any clinically significant abnormal hematology, chemistry, coagulation, or urinalysis
value, as determined by the principal investigator.

11. Glomerular filtration rate (GFR) of < 80 mL/min, based on the Modification of Diet in
Renal Disease equation.

12. Urine-albumin-to-creatinine ratio (UACR) > 30 mg/g.

13. Positive serology for Hepatitis B surface antigen

14. Positive serology for Anti Hepatitis C Antibody

15. Positive ELISA for HIV

16. Known or suspected exposure to Ebola virus.

17. Received investigational vaccine for prevention of EVD.

18. Received investigational treatment for EVD.